Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beauty Health (SKIN) Amortization of Deferred Charges (2020 - 2025)

Beauty Health (SKIN) has disclosed Amortization of Deferred Charges for 6 consecutive years, with $1.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Amortization of Deferred Charges rose 4.19% to $1.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.3 million, a 18.15% decrease, with the full-year FY2024 number at $3.3 million, up 36.25% from a year prior.
  • Amortization of Deferred Charges was $1.6 million for Q3 2025 at Beauty Health, up from $854000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $9.4 million in Q3 2021 to a low of -$9.2 million in Q4 2021.
  • A 5-year average of $528421.1 and a median of $786000.0 in 2025 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: tumbled 252.94% in 2021, then soared 980.0% in 2023.
  • Beauty Health's Amortization of Deferred Charges stood at -$9.2 million in 2021, then skyrocketed by 74.86% to -$2.3 million in 2022, then skyrocketed by 129.59% to $685000.0 in 2023, then tumbled by 100.29% to -$2000.0 in 2024, then surged by 82150.0% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for SKIN's Amortization of Deferred Charges are $1.6 million (Q3 2025), $854000.0 (Q2 2025), and $786000.0 (Q1 2025).